130 related articles for article (PubMed ID: 10362334)
1. Phase I-II trial of intensification of the MAID regimen with support of lenograstim (rHuG-CSF) in patients with advanced soft-tissue sarcoma (STS).
Chevreau C; Bui BN; Chevallier B; Krakowski I; Maugard C; Mihura J; Coindre JM; Gil B; Cour-Chabernaud V
Am J Clin Oncol; 1999 Jun; 22(3):267-72. PubMed ID: 10362334
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity.
Bui BN; Chevallier B; Chevreau C; Krakowski I; Peny AM; Thyss A; Maugard-Louboutin C; Cupissol D; Fargeot P; Bonichon F
J Clin Oncol; 1995 Oct; 13(10):2629-36. PubMed ID: 7595717
[TBL] [Abstract][Full Text] [Related]
3. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
4. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
Van Hoef ME; Baumann I; Lange C; Luft T; de Wynter EA; Ranson M; Morgenstern GR; Yvers A; Dexter TM; Testa NG
Ann Oncol; 1994 Mar; 5(3):217-24. PubMed ID: 7514434
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF did not allow doxorubicin dose escalation in the MAID regimen: a phase I trial. A Southwest Oncology Group study.
Hicks LG; Balcerzak SP; Zalupski M
Cancer Invest; 1996; 14(6):507-12. PubMed ID: 8951354
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas.
Ogura K; Goto T; Imanishi J; Shinoda Y; Okuma T; Tsuda Y; Kobayashi H; Akiyama T; Hirata M; Yamamoto A; Kawano H
Int J Clin Oncol; 2013 Feb; 18(1):170-6. PubMed ID: 22179493
[TBL] [Abstract][Full Text] [Related]
8. High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study.
Pronzato P; Losardo P; Pensa F; Tognoni A
Cancer Chemother Pharmacol; 1998; 41(6):513-6. PubMed ID: 9554597
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.
Le Cesne A; Judson I; Crowther D; Rodenhuis S; Keizer HJ; Van Hoesel Q; Blay JY; Frisch J; Van Glabbeke M; Hermans C; Van Oosterom A; Tursz T; Verweij J
J Clin Oncol; 2000 Jul; 18(14):2676-84. PubMed ID: 10894866
[TBL] [Abstract][Full Text] [Related]
10. Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas.
Pearl ML; Inagami M; McCauley DL; Valea FA; Chalas E; Fischer M
Int J Gynecol Cancer; 2002; 12(6):745-8. PubMed ID: 12445253
[TBL] [Abstract][Full Text] [Related]
11. Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma.
Elias A; Ryan L; Aisner J; Antman KH
Semin Oncol; 1990 Apr; 17(2 Suppl 4):41-9. PubMed ID: 2110385
[TBL] [Abstract][Full Text] [Related]
12. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.
Le Cesne A; Antoine E; Spielmann M; Le Chevalier T; Brain E; Toussaint C; Janin N; Kayitalire L; Fontaine F; Genin J
J Clin Oncol; 1995 Jul; 13(7):1600-8. PubMed ID: 7541449
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas.
DeLaney TF; Spiro IJ; Suit HD; Gebhardt MC; Hornicek FJ; Mankin HJ; Rosenberg AL; Rosenthal DI; Miryousefi F; Ancukiewicz M; Harmon DC
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1117-27. PubMed ID: 12829150
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children.
Womer RB; Daller RT; Fenton JG; Miser JS
Eur J Cancer; 2000 Jan; 36(1):87-94. PubMed ID: 10741300
[TBL] [Abstract][Full Text] [Related]
15. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
[TBL] [Abstract][Full Text] [Related]
16. Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas.
Michelotti A; Romanini A; Giannessi P; Bengala C; Conte P
Am J Clin Oncol; 1996 Feb; 19(1):78-81. PubMed ID: 8554042
[TBL] [Abstract][Full Text] [Related]
17. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Fayette J; Penel N; Chevreau C; Blay JY; Cupissol D; Thyss A; Guillemet C; Rios M; Rolland F; Fargeot P; Bay JO; Mathoulin-Pelissier S; Coindre JM; Bui-Nguyen B
Invest New Drugs; 2009 Oct; 27(5):482-9. PubMed ID: 19148579
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.
Bui-Nguyen B; Ray-Coquard I; Chevreau C; Penel N; Bay JO; Coindre JM; Cupissol D; Italiano A; Bonichon F; Lotz JP; Thyss A; Jimenez M; Mathoulin-Pélissier S; Blay JY;
Ann Oncol; 2012 Mar; 23(3):777-784. PubMed ID: 21652583
[TBL] [Abstract][Full Text] [Related]
19. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
Gatzemeier U; Kleisbauer JP; Drings P; Kaukel E; Samaras N; Melo MJ; Cardenal F; Robinet G; Snijder RJ; von Pawel J; Palisses R
Am J Clin Oncol; 2000 Aug; 23(4):393-400. PubMed ID: 10955871
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.
Gisselbrecht C; Haioun C; Lepage E; Bastion Y; Tilly H; Bosly A; Dupriez B; Marit G; Herbrecht R; Deconinck E; Marolleau JP; Yver A; Dabouz-Harrouche F; Coiffier B; Reyes F
Leuk Lymphoma; 1997 Apr; 25(3-4):289-300. PubMed ID: 9168439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
